Prothena Corp (PRTA)

$8.33 +0.42 (5.31%)
Market Cap 443.43M
Revenue (ttm) 9.68M
Net Income (ttm) -244.09M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 47.56
Profit Margin -2,521.59%
Debt to Equity Ratio 0.00
Volume 396,696
Avg Vol 492,030
Day's Range N/A - N/A
Shares Out 52.35M
Stochastic %K 1%
Beta -0.25
Analysts Sell
Price Target $21.40

Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of tr...

Industry: Biotechnology
Sector: Healthcare
Phone: 353 1 236 2500
Fax: 353 1 902 3510
Address:
77 Sir John Rogerson’s Quay, Block C Grand Canal Docklands, Dublin, Ireland
Guptasulo
Guptasulo Jun. 11 at 2:15 PM
$CGTX $PRTA $LLY $BIIB $ANVS For investors following AD, DLB and CNS: CGTX is building more than a single-asset story. DLB Psychosis: Registrational pathway 9 months trial supporting NDA following positive FDA interaction. SHINE:FDA's Phase 3-ready, 6-month dual-arm to NDA START: Ongoing Alzheimer's study in early, mild and moderate disease, Trial result expected completion in May 2027. Both SHINE+START trial covers Early, Mild and Moderate AD. Combined large AD trial for 2027 planned. Ph3 Psychosis is funded non-dilutive, Company is debt-free. Trial starts soon in 2026. Excellent Platform for CNS, no safety issues, and SHINE has proven efficacy though a small cohort CT1802 was pre-designed in the SHINE Trial.
1 · Reply
Estimize
Estimize Jun. 11 at 11:01 AM
Wall St is expecting -0.39 EPS for $PRTA Q2 [Reporting 08/10 AMC] http://www.estimize.com/intro/prta?chart=historical&metric_name=eps&utm_c
0 · Reply
Jtlo
Jtlo Jun. 10 at 6:26 PM
$PRTA makes me question a bit… the company has an authorization up to 100M at their discretion.l to buy back stock. It’s not low enough for them to pick up shares ?
0 · Reply
Jtlo
Jtlo Jun. 5 at 5:17 PM
$PRTA lol I bought in naturally it goes down
0 · Reply
Jtlo
Jtlo Jun. 5 at 3:41 PM
$PRTA I’m in. Fuck it. Grab 5.5K shares Good luck all
0 · Reply
Jtlo
Jtlo Jun. 5 at 2:49 PM
$PRTA can I get under 6?
0 · Reply
FilingTracker
FilingTracker Jun. 3 at 4:43 PM
$PRTA Insider purchase: https://www.sec.gov/Archives/edgar/data/1559053/000104546326000005/0001045463-26-000005-index.htm
0 · Reply
buyandsold
buyandsold May. 28 at 4:02 PM
$PRTA This has got to be the deadest money in the market. Valuable only because it won't decompose much further and it may yet arise like a zombie.
0 · Reply
SuperGreenToday
SuperGreenToday May. 28 at 2:39 PM
$PRTA Share Price: $10.02 Contract Selected: Dec 18, 2026 $11.0 Calls Buy Zone: $0.94 – $1.16 Target Zone: $1.75 – $2.14 Potential Upside: 77% ROI Time to Expiration: 203 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
buyandsold
buyandsold May. 27 at 1:36 PM
$PRTA William P. Scully, a 10% owner, reported a direct purchase of ordinary shares in Prothena. The total purchase amount reported was $981,300. Is this the same Bill Scully who was sentenced to 60 months in prison?
0 · Reply
Latest News on PRTA
Prothena price target raised to $20 from $19 at Citizens

2026-05-08T10:14:04.000Z - 4 weeks ago

Prothena price target raised to $20 from $19 at Citizens

Prothena cuts FY26 net cash used view to $18M-$23M from $50M-$55M

2026-05-07T22:35:54.000Z - 4 weeks ago

Prothena cuts FY26 net cash used view to $18M-$23M from $50M-$55M

Prothena Reports First Quarter 2026 Financial Results and Business Highlights

May 7, 2026, 4:05 PM EDT - 4 weeks ago

Prothena Reports First Quarter 2026 Financial Results and Business Highlights

Prothena Corporation Earnings release: Q1 2026

May 7, 2026, 4:00 PM EDT - 4 weeks ago

Prothena Corporation Earnings release: Q1 2026

Prothena Corporation Quarterly report: Q1 2026

May 7, 2026, 4:00 PM EDT - 4 weeks ago

Prothena Corporation Quarterly report: Q1 2026

Prothena Corporation Slides: Corporate presentation

May 5, 2026, 4:45 PM EDT - 5 weeks ago

Prothena Corporation Slides: Corporate presentation

Prothena to Report First Quarter 2026 Financial Results on May 7

Apr 30, 2026, 4:05 PM EDT - 5 weeks ago

Prothena to Report First Quarter 2026 Financial Results on May 7

Prothena announces Novo Nordisk obtained FDA fast track for PRX004

2026-04-27T20:37:06.000Z - 6 weeks ago

Prothena announces Novo Nordisk obtained FDA fast track for PRX004

NVO

Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy

Apr 27, 2026, 4:05 PM EDT - 6 weeks ago

Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy

Prothena names Annie Kingston as Chief Strategy Officer

2026-04-10T20:10:31.000Z - 2 months ago

Prothena names Annie Kingston as Chief Strategy Officer

Prothena Announces Leadership Team Updates

Apr 10, 2026, 4:05 PM EDT - 2 months ago

Prothena Announces Leadership Team Updates

Prothena Corporation Proxy statement: Proxy filing

Mar 27, 2026, 8:00 AM EDT - 2 months ago

Prothena Corporation Proxy statement: Proxy filing

Prothena Corporation Proxy statement: Proxy filing

Mar 27, 2026, 8:00 AM EDT - 2 months ago

Prothena Corporation Proxy statement: Proxy filing

Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson's and Alzheimer's Disease at AD/PD™ 2026

Mar 21, 2026, 4:05 PM EDT - 2 months ago

Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson's and Alzheimer's Disease at AD/PD™ 2026

Prothena Corporation Transcript: The Citizens Life Sciences Conference 2026

Mar 11, 2026, 10:10 AM EDT - 3 months ago

Prothena Corporation Transcript: The Citizens Life Sciences Conference 2026

Prothena achieves $50M clinical milestone payment from Novo Nordisk

2026-03-09T20:11:30.000Z - 3 months ago

Prothena achieves $50M clinical milestone payment from Novo Nordisk

NVO

Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy

Mar 9, 2026, 4:05 PM EDT - 3 months ago

Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy

Prothena Corporation Slides: Corporate presentation

Mar 9, 2026, 7:00 AM EDT - 3 months ago

Prothena Corporation Slides: Corporate presentation

Prothena announces $100M share repurchase plan

2026-02-27T21:20:51.000Z - 3 months ago

Prothena announces $100M share repurchase plan

Prothena expects to end year with $255M in cash, equivalents

2026-02-27T21:20:25.000Z - 3 months ago

Prothena expects to end year with $255M in cash, equivalents

BMY NVO

Prothena Announces up to $100 Million Share Repurchase Plan

Feb 27, 2026, 4:15 PM EST - 3 months ago

Prothena Announces up to $100 Million Share Repurchase Plan

Prothena Corporation Earnings Call Transcript: Q4 2025

Feb 19, 2026, 4:30 PM EST - 3 months ago

Prothena Corporation Earnings Call Transcript: Q4 2025

Prothena Corporation Annual report: Q4 2025

Feb 19, 2026, 4:30 PM EST - 3 months ago

Prothena Corporation Annual report: Q4 2025

Prothena Corporation Earnings release: Q4 2025

Feb 19, 2026, 4:30 PM EST - 3 months ago

Prothena Corporation Earnings release: Q4 2025

Prothena Corporation Slides: Q4 2025

Feb 19, 2026, 4:30 PM EST - 3 months ago

Prothena Corporation Slides: Q4 2025

Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights

Feb 19, 2026, 4:05 PM EST - 3 months ago

Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights

Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026

Feb 12, 2026, 4:05 PM EST - 4 months ago

Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026

Prothena Announces Board of Directors Update

Dec 12, 2025, 4:05 PM EST - 6 months ago

Prothena Announces Board of Directors Update

Prothena Corporation Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 4, 2025, 10:50 AM EST - 6 months ago

Prothena Corporation Transcript: Evercore ISI 8th Annual HealthCONx Conference

Prothena Corporation Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 3, 2025, 1:00 PM EST - 6 months ago

Prothena Corporation Transcript: Piper Sandler 37th Annual Healthcare Conference

Prothena price target raised to $19 from $11 at Citizens JMP

2025-12-01T10:40:23.000Z - 6 months ago

Prothena price target raised to $19 from $11 at Citizens JMP

Prothena price target raised to $8 from $4 at BofA

2025-11-24T14:16:05.000Z - 7 months ago

Prothena price target raised to $8 from $4 at BofA

NVO

Prothena announces poster presentation on TDP-43 CYTOPE program

2025-11-19T21:10:54.000Z - 7 months ago

Prothena announces poster presentation on TDP-43 CYTOPE program

Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025

Nov 19, 2025, 4:05 PM EST - 7 months ago

Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025

Prothena highlights positive Phase 2 Coramitug data published in AHA journal

2025-11-11T14:15:23.000Z - 7 months ago

Prothena highlights positive Phase 2 Coramitug data published in AHA journal

NVO

Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA

Nov 11, 2025, 9:00 AM EST - 7 months ago

Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA

Prothena price target raised to $30 from $20 at H.C. Wainwright

2025-11-07T14:26:08.000Z - 7 months ago

Prothena price target raised to $30 from $20 at H.C. Wainwright

Prothena Reports Third Quarter 2025 Financial Results and Business Highlights

Nov 6, 2025, 4:05 PM EST - 7 months ago

Prothena Reports Third Quarter 2025 Financial Results and Business Highlights

Prothena Corporation Quarterly report: Q3 2025

Nov 6, 2025, 4:00 PM EST - 7 months ago

Prothena Corporation Quarterly report: Q3 2025

Prothena Corporation Earnings release: Q3 2025

Nov 6, 2025, 4:00 PM EST - 7 months ago

Prothena Corporation Earnings release: Q3 2025

Prothena Corporation Proxy statement: Proxy Filing

Nov 6, 2025, 7:00 AM EST - 7 months ago

Prothena Corporation Proxy statement: Proxy Filing

Prothena to Report Third Quarter 2025 Financial Results on November 6

Oct 30, 2025, 4:05 PM EDT - 7 months ago

Prothena to Report Third Quarter 2025 Financial Results on November 6

Prothena price target raised to $36 from $15 at Piper Sandler

2025-10-28T10:41:09.000Z - 8 months ago

Prothena price target raised to $36 from $15 at Piper Sandler

Prothena price target raised to $20 from $14 at H.C. Wainwright

2025-10-07T12:35:38.000Z - 8 months ago

Prothena price target raised to $20 from $14 at H.C. Wainwright

Prothena Corporation Proxy statement: Proxy Filing

Oct 7, 2025, 8:00 AM EDT - 8 months ago

Prothena Corporation Proxy statement: Proxy Filing

Prothena Corporation Proxy statement: Proxy Filing

Oct 7, 2025, 8:00 AM EDT - 8 months ago

Prothena Corporation Proxy statement: Proxy Filing

Prothena says partner Bristol Myers Squibb’ BMS-986446 granted FDA fast-track

2025-10-01T20:55:20.000Z - 9 months ago

Prothena says partner Bristol Myers Squibb’ BMS-986446 granted FDA fast-track

BMY

Prothena's Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer's Disease

Oct 1, 2025, 4:45 PM EDT - 9 months ago

Prothena's Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer's Disease

Prothena Corporation Proxy statement: Proxy Filing

Sep 25, 2025, 8:00 AM EDT - 9 months ago

Prothena Corporation Proxy statement: Proxy Filing

Prothena Corporation Transcript: Cantor Global Healthcare Conference 2025

Sep 4, 2025, 10:55 AM EDT - 10 months ago

Prothena Corporation Transcript: Cantor Global Healthcare Conference 2025

Prothena price target lowered to $11 from $29 at Citizens JMP

2025-09-02T10:40:29.000Z - 10 months ago

Prothena price target lowered to $11 from $29 at Citizens JMP

Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference

Aug 28, 2025, 4:05 PM EDT - 10 months ago

Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference

Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program

Aug 27, 2025, 4:05 PM EDT - 10 months ago

Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program

Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy

Aug 6, 2025, 9:00 AM EDT - 11 months ago

Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy

Prothena Reports Second Quarter 2025 Financial Results and Business Highlights

Aug 4, 2025, 4:05 PM EDT - 11 months ago

Prothena Reports Second Quarter 2025 Financial Results and Business Highlights

Prothena Corporation Quarterly report: Q2 2025

Aug 4, 2025, 4:00 PM EDT - 11 months ago

Prothena Corporation Quarterly report: Q2 2025

Prothena Corporation Earnings release: Q2 2025

Aug 4, 2025, 4:00 PM EDT - 11 months ago

Prothena Corporation Earnings release: Q2 2025

Prothena to Report Second Quarter 2025 Financial Results on August 4

Jul 28, 2025, 4:05 PM EDT - 11 months ago

Prothena to Report Second Quarter 2025 Financial Results on August 4

Prothena Announces Corporate Restructuring

Jun 18, 2025, 4:05 PM EDT - 1 year ago

Prothena Announces Corporate Restructuring

Prothena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease

Jun 16, 2025, 1:06 AM EDT - 1 year ago

Prothena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease

Prothena Corporation Slides: Corporate Presentation

Jun 15, 2025, 7:00 AM EDT - 1 year ago

Prothena Corporation Slides: Corporate Presentation

Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint

May 23, 2025, 4:05 PM EDT - 1 year ago

Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint

Prothena Corporation Slides: Corporate Presentation

May 23, 2025, 7:00 AM EDT - 1 year ago

Prothena Corporation Slides: Corporate Presentation

Prothena Reports First Quarter 2025 Financial Results and Business Highlights

May 8, 2025, 4:05 PM EDT - 1 year ago

Prothena Reports First Quarter 2025 Financial Results and Business Highlights

Prothena Corporation Quarterly report: Q1 2025

May 8, 2025, 4:00 PM EDT - 1 year ago

Prothena Corporation Quarterly report: Q1 2025

Prothena Corporation Earnings release: Q1 2025

May 8, 2025, 4:00 PM EDT - 1 year ago

Prothena Corporation Earnings release: Q1 2025

Prothena to Report First Quarter 2025 Financial Results on May 8

May 1, 2025, 4:05 PM EDT - 1 year ago

Prothena to Report First Quarter 2025 Financial Results on May 8

Prothena Corporation Proxy statement: Proxy Filing

Mar 28, 2025, 8:00 AM EDT - 1 year ago

Prothena Corporation Proxy statement: Proxy Filing

Prothena Corporation Proxy statement: Proxy Filing

Mar 28, 2025, 8:00 AM EDT - 1 year ago

Prothena Corporation Proxy statement: Proxy Filing

Prothena Corporation Earnings Call Transcript: Q4 2024

Feb 20, 2025, 4:30 PM EST - 1 year ago

Prothena Corporation Earnings Call Transcript: Q4 2024

Prothena Corporation Annual report: Q4 2024

Feb 20, 2025, 4:30 PM EST - 1 year ago

Prothena Corporation Annual report: Q4 2024

Prothena Corporation Earnings release: Q4 2024

Feb 20, 2025, 4:30 PM EST - 1 year ago

Prothena Corporation Earnings release: Q4 2024

Prothena Corporation Slides: Q4 2024

Feb 20, 2025, 4:30 PM EST - 1 year ago

Prothena Corporation Slides: Q4 2024

Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights

Feb 20, 2025, 4:05 PM EST - 1 year ago

Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights

Prothena Corporation Slides: Corporate Presentation

Feb 20, 2025, 7:00 AM EST - 1 year ago

Prothena Corporation Slides: Corporate Presentation

Kuehn Law Encourages Investors of Prothena Corporation PLC to Contact Law Firm

Feb 17, 2025, 6:10 PM EST - 1 year ago

Kuehn Law Encourages Investors of Prothena Corporation PLC to Contact Law Firm

Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025

Feb 13, 2025, 4:05 PM EST - 1 year ago

Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025

Prothena Corporation Slides: Corporate Presentation

Jan 10, 2025, 7:00 AM EST - 1 year ago

Prothena Corporation Slides: Corporate Presentation

Roche's Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson's Disease

Dec 19, 2024, 1:05 AM EST - 1 year ago

Roche's Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson's Disease

Prothena Reports Third Quarter 2024 Financial Results and Business Highlights

Nov 12, 2024, 4:05 PM EST - 1 year ago

Prothena Reports Third Quarter 2024 Financial Results and Business Highlights

Prothena Corporation Earnings release: Q3 2024

Nov 12, 2024, 4:00 PM EST - 1 year ago

Prothena Corporation Earnings release: Q3 2024

Prothena Corporation Quarterly report: Q3 2024

Nov 12, 2024, 4:00 PM EST - 1 year ago

Prothena Corporation Quarterly report: Q3 2024

Prothena Corporation Slides: Corporate Presentation

Nov 12, 2024, 7:00 AM EST - 1 year ago

Prothena Corporation Slides: Corporate Presentation

Prothena to Report Third Quarter 2024 Financial Results on November 12

Nov 5, 2024, 4:05 PM EST - 1 year ago

Prothena to Report Third Quarter 2024 Financial Results on November 12

Prothena Corporation Slides: Corporate Presentation

Sep 26, 2024, 7:00 AM EDT - 1 year ago

Prothena Corporation Slides: Corporate Presentation

Prothena Corporation Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 17, 2024, 1:55 PM EDT - 1 year ago

Prothena Corporation Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Prothena to Participate in Upcoming Healthcare Conferences

Aug 29, 2024, 4:05 PM EDT - 1 year ago

Prothena to Participate in Upcoming Healthcare Conferences

Prothena Reports Second Quarter 2024 Financial Results and Business Highlights

Aug 8, 2024, 4:05 PM EDT - 1 year ago

Prothena Reports Second Quarter 2024 Financial Results and Business Highlights

Prothena Corporation Quarterly report: Q2 2024

Aug 8, 2024, 4:00 PM EDT - 1 year ago

Prothena Corporation Quarterly report: Q2 2024

Prothena Corporation Earnings release: Q2 2024

Aug 8, 2024, 4:00 PM EDT - 1 year ago

Prothena Corporation Earnings release: Q2 2024

Prothena Corporation Slides: Corporate Presentation

Aug 8, 2024, 7:00 AM EDT - 2 years ago

Prothena Corporation Slides: Corporate Presentation

Prothena to Report Second Quarter 2024 Financial Results on August 8

Aug 1, 2024, 4:05 PM EDT - 2 years ago

Prothena to Report Second Quarter 2024 Financial Results on August 8

Prothena Corporation Slides: Corporate Presentation

Jul 28, 2024, 7:00 AM EDT - 2 years ago

Prothena Corporation Slides: Corporate Presentation

Prothena Corporation Slides: Corporate Presentation

May 29, 2024, 7:00 AM EDT - 2 years ago

Prothena Corporation Slides: Corporate Presentation

Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration

May 28, 2024, 4:05 PM EDT - 2 years ago

Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration

Prothena Reports First Quarter 2024 Financial Results and Business Highlights

May 8, 2024, 4:05 PM EDT - 2 years ago

Prothena Reports First Quarter 2024 Financial Results and Business Highlights

Prothena Corporation Quarterly report: Q1 2024

May 8, 2024, 4:00 PM EDT - 2 years ago

Prothena Corporation Quarterly report: Q1 2024

Prothena Corporation Earnings release: Q1 2024

May 8, 2024, 4:00 PM EDT - 2 years ago

Prothena Corporation Earnings release: Q1 2024

Prothena Corporation Slides: Corporate Presentation

May 8, 2024, 7:00 AM EDT - 2 years ago

Prothena Corporation Slides: Corporate Presentation

Prothena to Report First Quarter 2024 Financial Results on May 8

May 1, 2024, 4:05 PM EDT - 2 years ago

Prothena to Report First Quarter 2024 Financial Results on May 8

Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma

Apr 15, 2024, 4:05 PM EDT - 2 years ago

Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma

Prothena Corporation Proxy statement: Proxy Filing

Mar 29, 2024, 8:00 AM EDT - 2 years ago

Prothena Corporation Proxy statement: Proxy Filing

Prothena Corporation Proxy statement: Proxy Filing

Mar 29, 2024, 8:00 AM EDT - 2 years ago

Prothena Corporation Proxy statement: Proxy Filing

Prothena Corporation Transcript: Leerink Partners Global Biopharma Conference 2024

Mar 12, 2024, 10:00 AM EDT - 2 years ago

Prothena Corporation Transcript: Leerink Partners Global Biopharma Conference 2024

Prothena Appoints David Ford to Newly Created Chief People Officer Position

Mar 4, 2024, 4:05 PM EST - 2 years ago

Prothena Appoints David Ford to Newly Created Chief People Officer Position

Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate

Feb 21, 2024, 4:05 PM EST - 2 years ago

Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate

Prothena Corporation Earnings Call Transcript: Q4 2023

Feb 15, 2024, 4:30 PM EST - 2 years ago

Prothena Corporation Earnings Call Transcript: Q4 2023

Prothena Corporation Annual report: Q4 2023

Feb 15, 2024, 4:30 PM EST - 2 years ago

Prothena Corporation Annual report: Q4 2023

Prothena Corporation Earnings release: Q4 2023

Feb 15, 2024, 4:30 PM EST - 2 years ago

Prothena Corporation Earnings release: Q4 2023

Prothena Corporation Slides: Q4 2023

Feb 15, 2024, 4:30 PM EST - 2 years ago

Prothena Corporation Slides: Q4 2023

Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights

Feb 15, 2024, 4:05 PM EST - 2 years ago

Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights

Prothena Corporation Slides: Corporate Presentation

Feb 14, 2024, 6:00 PM EST - 2 years ago

Prothena Corporation Slides: Corporate Presentation

Prothena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024

Feb 8, 2024, 4:05 PM EST - 2 years ago

Prothena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024

Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs

Jan 8, 2024, 8:30 AM EST - 2 years ago

Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs

Prothena Corporation Slides: Corporate Presentation

Jan 8, 2024, 7:00 AM EST - 2 years ago

Prothena Corporation Slides: Corporate Presentation

Prothena Reports Third Quarter 2023 Financial Results and Business Highlights

Nov 2, 2023, 4:05 PM EDT - 2 years ago

Prothena Reports Third Quarter 2023 Financial Results and Business Highlights

Prothena Corporation Quarterly report: Q3 2023

Nov 2, 2023, 8:00 AM EDT - 2 years ago

Prothena Corporation Quarterly report: Q3 2023

Prothena Corporation Earnings release: Q3 2023

Nov 2, 2023, 8:00 AM EDT - 2 years ago

Prothena Corporation Earnings release: Q3 2023

Prothena Corporation Slides: Corporate Presentation

Nov 2, 2023, 8:00 AM EDT - 2 years ago

Prothena Corporation Slides: Corporate Presentation

Prothena to Report Third Quarter 2023 Financial Results on November 2

Oct 26, 2023, 4:05 PM EDT - 2 years ago

Prothena to Report Third Quarter 2023 Financial Results on November 2

Prothena prepares for potential sale - Bloomberg News

Oct 16, 2023, 11:57 AM EDT - 2 years ago

Prothena prepares for potential sale - Bloomberg News

Prothena Corporation Transcript: Morgan Stanley 21st Annual Global Healthcare Conference 2023

Sep 11, 2023, 2:15 PM EDT - 2 years ago

Prothena Corporation Transcript: Morgan Stanley 21st Annual Global Healthcare Conference 2023

Prothena Reports Second Quarter 2023 Financial Results and Business Highlights

Aug 3, 2023, 4:05 PM EDT - 3 years ago

Prothena Reports Second Quarter 2023 Financial Results and Business Highlights

Prothena Corporation Quarterly report: Q2 2023

Aug 3, 2023, 4:00 PM EDT - 3 years ago

Prothena Corporation Quarterly report: Q2 2023

Prothena Corporation Earnings release: Q2 2023

Aug 3, 2023, 4:00 PM EDT - 3 years ago

Prothena Corporation Earnings release: Q2 2023

Prothena Corporation Slides: Corporate Presentation

Aug 3, 2023, 1:30 PM EDT - 3 years ago

Prothena Corporation Slides: Corporate Presentation

Prothena to Report Second Quarter 2023 Financial Results on August 3

Jul 27, 2023, 4:05 PM EDT - 3 years ago

Prothena to Report Second Quarter 2023 Financial Results on August 3

Prothena Presents New Research in the Treatment of Alzheimer's Disease at Alzheimer's Association International Conference® 2023 (AAIC®)

Jul 17, 2023, 8:35 AM EDT - 3 years ago

Prothena Presents New Research in the Treatment of Alzheimer's Disease at Alzheimer's Association International Conference® 2023 (AAIC®)

Prothena to Present New Data from Alzheimer's Disease Programs at Alzheimer's Association International Conference® 2023 (AAIC®)

Jul 11, 2023, 4:05 PM EDT - 3 years ago

Prothena to Present New Data from Alzheimer's Disease Programs at Alzheimer's Association International Conference® 2023 (AAIC®)

Guptasulo
Guptasulo Jun. 11 at 2:15 PM
$CGTX $PRTA $LLY $BIIB $ANVS For investors following AD, DLB and CNS: CGTX is building more than a single-asset story. DLB Psychosis: Registrational pathway 9 months trial supporting NDA following positive FDA interaction. SHINE:FDA's Phase 3-ready, 6-month dual-arm to NDA START: Ongoing Alzheimer's study in early, mild and moderate disease, Trial result expected completion in May 2027. Both SHINE+START trial covers Early, Mild and Moderate AD. Combined large AD trial for 2027 planned. Ph3 Psychosis is funded non-dilutive, Company is debt-free. Trial starts soon in 2026. Excellent Platform for CNS, no safety issues, and SHINE has proven efficacy though a small cohort CT1802 was pre-designed in the SHINE Trial.
1 · Reply
Estimize
Estimize Jun. 11 at 11:01 AM
Wall St is expecting -0.39 EPS for $PRTA Q2 [Reporting 08/10 AMC] http://www.estimize.com/intro/prta?chart=historical&metric_name=eps&utm_c
0 · Reply
Jtlo
Jtlo Jun. 10 at 6:26 PM
$PRTA makes me question a bit… the company has an authorization up to 100M at their discretion.l to buy back stock. It’s not low enough for them to pick up shares ?
0 · Reply
Jtlo
Jtlo Jun. 5 at 5:17 PM
$PRTA lol I bought in naturally it goes down
0 · Reply
Jtlo
Jtlo Jun. 5 at 3:41 PM
$PRTA I’m in. Fuck it. Grab 5.5K shares Good luck all
0 · Reply
Jtlo
Jtlo Jun. 5 at 2:49 PM
$PRTA can I get under 6?
0 · Reply
FilingTracker
FilingTracker Jun. 3 at 4:43 PM
$PRTA Insider purchase: https://www.sec.gov/Archives/edgar/data/1559053/000104546326000005/0001045463-26-000005-index.htm
0 · Reply
buyandsold
buyandsold May. 28 at 4:02 PM
$PRTA This has got to be the deadest money in the market. Valuable only because it won't decompose much further and it may yet arise like a zombie.
0 · Reply
SuperGreenToday
SuperGreenToday May. 28 at 2:39 PM
$PRTA Share Price: $10.02 Contract Selected: Dec 18, 2026 $11.0 Calls Buy Zone: $0.94 – $1.16 Target Zone: $1.75 – $2.14 Potential Upside: 77% ROI Time to Expiration: 203 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
buyandsold
buyandsold May. 27 at 1:36 PM
$PRTA William P. Scully, a 10% owner, reported a direct purchase of ordinary shares in Prothena. The total purchase amount reported was $981,300. Is this the same Bill Scully who was sentenced to 60 months in prison?
0 · Reply
FilingTracker
FilingTracker May. 26 at 6:52 PM
$PRTA Large insider purchase: https://www.sec.gov/Archives/edgar/data/1559053/000104546326000004/0001045463-26-000004-index.htm
0 · Reply
Quantumup
Quantumup May. 26 at 12:47 PM
H.C. Wainwright (a/o 5/22)⬆️ $IMMX's PT to $20,⬆️NXC-201 PoA in r/r AL amyloidosis to 90% and⬆️projected peak market penetration in this indication to 55% while reiterating at Buy. $PRTA ABBV REGN AZN $JNJ - GMAB Here's what else H.C. Wainwright had to say: https://x.com/Quantumup1/status/2059254483155145192?s=20
0 · Reply
AIBioScanner
AIBioScanner May. 25 at 8:04 AM
$PRTA AI-Based Findings on PRTA After running PRTA through my AI-driven quantitative framework, the stock is in a downtrend with price falling below both moving averages amid weakening momentum. PRTA is trading around $9.83, below both the 20-day (~$10.24) and 50-day (~$10.03) moving averages — indicating continued selling pressure and softening structure. Key signals: • Trading below both MAs — downtrend • MACD negative (-0.25) — bearish momentum • Range between ~$9.07 support and ~$11.51 resistance 1-Month Outlook: Base scenario: consolidation near $9.34–$10.32 Breakout above $10.32 could open a move toward $12.08 Breakdown below $9.34 may extend further downside toward $7.66 Structure is bearish. Requires significant catalyst or volume reversal for recovery. Not financial advice.
0 · Reply
buyandsold
buyandsold May. 22 at 8:56 PM
$PRTA I don't think there are any buyers for the company outright because who buys what is in effect a basket of CVRs for such a large amount? Maybe a PE firm but kind of rare. Management basically has no pressure to sell so they can just sit and collect, salaries. The only way we're going to get paid is when the event catalysts take place. We can't really bring any pressure to bear on management to do the right thing and cut their staff. I mean really this thing should be sold to someone for cash plus CVRs or just run as a shell.
0 · Reply
BioRich
BioRich May. 20 at 7:07 AM
$AVXL $NUVL $GPCR $OPTT $PRTA (Sorry, Placeholders) Cheers!
1 · Reply
buyandsold
buyandsold May. 19 at 6:37 PM
$PRTA I respectfully disagree with the price action and require $14 herewith
0 · Reply
NVDAMillionaire
NVDAMillionaire May. 19 at 6:08 PM
$PRTA Great piece that accurately captures PRTA's current position. So if you want to refresh your understanding of PRTA or learn about PRTA for the first time, this is essential reading. https://everyticker.com/quote/PRTA/analysis/prothena-s-partnership-pivot-from-pipeline-risk-to-platform-value-nasdaq-prta
0 · Reply
takingstock73
takingstock73 May. 11 at 4:14 PM
$PRTA any rumor why this is dipping ?
3 · Reply
tumanako
tumanako May. 8 at 11:06 AM
$PRTA Institutional accumulations
0 · Reply
buyandsold
buyandsold May. 5 at 6:14 PM
$PRTA The share count was approximately 53.8 million ordinary shares as of February 12, 2026 (just before the buyback was announced on February 27), and the proxy statement filed in late March 2026 still showed 53,832,982 shares outstanding as of the March 2, 2026 record date. That's essentially no change over a period when buybacks would have started showing up if they were buying aggressively.
0 · Reply
French_Vibe
French_Vibe Apr. 27 at 8:12 PM
$PRTA $NVO https://ir.prothena.com/investors/press-releases/news-details/2026/Prothena-Announces-Novo-Nordisk-Obtains-Fast-Track-Designation-from-the-U-S--FDA-for-Coramitug-PRX004-in-ATTR-Amyloidosis-with-Cardiomyopathy/default.aspx
0 · Reply
Sambong
Sambong Apr. 23 at 4:28 PM
$PRTA 🤔🤔👀👀
0 · Reply